SGO Annual Meeting

Two Analyses Describe Patient Preferences for Maintenance Therapy in Ovarian Cancer

April 25, 2020

In an interview with Targeted Oncology, Charlotte Sun, DrPH, MPH, discussed the findings from 2 abstracts from the 2020 SGO Annual Meeting on patient preferences for maintenance therapy in ovarian cancer and how these findings can be applied to practice in the community oncology setting.

Targeted Agent Demonstrates Strong Activity in Uterine Serous Carcinoma

April 24, 2020

"Adavosertib demonstrated promising preliminary clinical activity in patients with unselected uterine serous cancer."

PARP Inhibitor Costs Give Patients With Ovarian Cancer Financial Toxicity

April 24, 2020

Ross F. Harrison, MD, discusses the out-of-pocket costs for patients with ovarian cancer receiving PARP inhibitor treatment.

Dostarlimab on the Road to Progress in dMMR Endometrial Cancer

April 24, 2020

“There are limited treatment options for women with advanced or recurrent endometrial cancer, and prognosis of these patients is poor. The results observed in the GARNET trial indicate the potential of dostarlimab to offer a new treatment option for women with this challenging disease.”

Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer

April 17, 2020

Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival over chemotherapy.

Veliparib Spotlighted for Antitumor Efficacy in Ovarian Cancer

April 15, 2020

In the phase III VELIA trial, the addition of veliparib to frontline induction chemotherapy expanded the number of complete responses and CA-125 responses in patients with high-grade serous ovarian cancer compared with chemotherapy alone, according to results from an exploratory analysis.

Vigil Immunotherapy Prolongs RFS as Frontline Maintenance Treatment in Ovarian Cancer

April 14, 2020

Relapse-free survival was prolonged in patients with stage III/IV ovarian cancer who received frontline maintenance treatment with Vigil immunotherapy compared with placebo. This was especially true for patients with BRCA1/2 wild-type disease, according to results from the phase II VITAL study.

Frontline Niraparib Plus Bevacizumab for Advanced Ovarian Cancer Yields Promising Activity

April 13, 2020

Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II OVARIO trial.

Analyses of Frontline Niraparib Maintenance Demonstrate Positive Patient-Reported Outcomes in Ovarian Cancer

April 11, 2020

Following its success in the phase III PRIMA study, frontline niraparib maintenance demonstrated positive patient-reported outcomes, as well as met biomarker-defined and other secondary endpoints, according to 3 analyses to be reported as part of the Society of Gynecologic Oncology 2020 Annual Meeting.